SAN

77.59

+1.09%↑

ARGX

707

+2.76%↑

SHL.DE

34.48

+0.5%↑

FRE

-0.4%↓

PHIA

23.2

+0.91%↑

SAN

77.59

+1.09%↑

ARGX

707

+2.76%↑

SHL.DE

34.48

+0.5%↑

FRE

-0.4%↓

PHIA

23.2

+0.91%↑

SAN

77.59

+1.09%↑

ARGX

707

+2.76%↑

SHL.DE

34.48

+0.5%↑

FRE

-0.4%↓

PHIA

23.2

+0.91%↑

SAN

77.59

+1.09%↑

ARGX

707

+2.76%↑

SHL.DE

34.48

+0.5%↑

FRE

-0.4%↓

PHIA

23.2

+0.91%↑

SAN

77.59

+1.09%↑

ARGX

707

+2.76%↑

SHL.DE

34.48

+0.5%↑

FRE

-0.4%↓

PHIA

23.2

+0.91%↑

Home・Listă Acțiuni・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Închisă

SectorSănătate

59.85 0.5

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

59.25

Maxim

Indicatori cheie
By Trading Economics
Venit	-33M 9.5M
Vânzări	-66M 152M
P/E Medie Sector	24.576 49.701
EPS	0.185
Marjă de profit	6.216
Angajați	1,950
EBITDA	-45M 18M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+26.46% upside

Dividende
By Dow Jones
Următoarele câștiguri	23 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-1.1B 3B
Deschiderea anterioară	59.35
Închiderea anterioară	59.85

Sentimentul știrilor

By Acuity

50%

159 / 345 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

51.1 / N/A Suport & Rezistență

Laboratorios Farmaceuticos Rovi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

20 mai 2026, 23:31 UTC

Acțiuni populare

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20 mai 2026, 22:52 UTC

Principalele dinamici ale pieței

Osisko Shares Fall on Planned Convertible Notes Offering

20 mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20 mai 2026, 23:44 UTC

Câștiguri

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20 mai 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20 mai 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20 mai 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20 mai 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20 mai 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20 mai 2026, 23:14 UTC

Câștiguri

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20 mai 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20 mai 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20 mai 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20 mai 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20 mai 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20 mai 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 mai 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20 mai 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20 mai 2026, 22:10 UTC

Câștiguri

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20 mai 2026, 22:00 UTC

Câștiguri

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20 mai 2026, 21:38 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20 mai 2026, 21:27 UTC

Câștiguri

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20 mai 2026, 21:20 UTC

Câștiguri

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20 mai 2026, 21:19 UTC

Câștiguri

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20 mai 2026, 21:18 UTC

Câștiguri

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20 mai 2026, 21:17 UTC

Câștiguri

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20 mai 2026, 21:17 UTC

Câștiguri

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20 mai 2026, 21:17 UTC

Câștiguri

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20 mai 2026, 21:16 UTC

Câștiguri

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Comparație

Modificare preț

Laboratorios Farmaceuticos Rovi SA Așteptări

Obiectiv de preț

By TipRanks

26.46% sus

Prognoză pe 12 luni

Medie 73.6 EUR 26.46%

Maxim 83 EUR

Minim 64.2 EUR

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLaboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 2 analiști care au acordat evaluări ale acțiunilor Laboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

51.1 / N/ASuport & Rezistență

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

159 / 345 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.